Substance / Medication

Tazemetostat

Overview

Active Ingredient
tazemetostat
RxNorm CUI
2274378

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study.
Palomba Maria Lia, Cartron Guillaume, Popplewell Leslie et al. · Clin Lymphoma Myeloma Leuk · 2022
PMID: 35151584Trial
Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score-matched analysis of E7438-G000-101 trial outcomes.
Proudman David G, Gupta Deepshekhar, Nellesen Dave et al. · Oncotarget · 2022
PMID: 35574216TrialFull text (PMC)
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.
Zauderer Marjorie G, Szlosarek Peter W, Le Moulec Sylvestre et al. · Lancet Oncol · 2022
PMID: 35588752Trial
Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.
Munakata Wataru, Shirasugi Yukari, Tobinai Kensei et al. · Cancer Sci · 2021
PMID: 33492746TrialFull text (PMC)
Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.
Izutsu Koji, Ando Kiyoshi, Nishikori Momoko et al. · Cancer Sci · 2021
PMID: 34159682TrialFull text (PMC)
A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features.
Sarkozy Clémentine, Morschhauser Franck, Dubois Sydney et al. · Clin Cancer Res · 2020
PMID: 32122924Trial
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
Morschhauser Franck, Tilly Hervé, Chaidos Aristeidis et al. · Lancet Oncol · 2020
PMID: 33035457TrialFull text (PMC)
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
Gounder Mrinal, Schöffski Patrick, Jones Robin L et al. · Lancet Oncol · 2020
PMID: 33035459Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tazemetostat (substance)
SNOMED CT
840405005
UMLS CUI
C4086895
RxNorm CUI
2274378

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.